Are you currently working on developing an antibody or other biologic? Do you have a target and are wondering if an antibody is the right approach? Join us on Wednesday May 6 for a research-focused seminar with Dr. Ivo Lorenz, VP & Head of Biologics, from Deerfield Discovery and Development. Ivo joined Deerfield in 2021. Prior to Deerfield, Dr. Lorenz was Vice President, Biologics at the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). Before the Tri-I TDI, he had group leader positions in R&D at Boehringer Ingelheim Pharmaceuticals and at the International AIDS Vaccine Initiative (IAVI). Dr. Lorenz holds a Ph.D. in Biochemistry and an M.Sc. and a B.Sc. in Biochemistry and Molecular Biology from the Swiss Federal Institute of Technology in Zurich.
This seminar will focus on the antibody drug discovery pipeline––from target selection and hit generation through lead optimization and early developability assessment, highlighting different considerations such as the key scientific and practical decisions that shape whether an antibody can become a viable therapeutic.
Event Details:
- Date: Wednesday, May 6
- Time: 1:30-2:30 PM
- Location: CLS 3 Conference Room
- RSVP: here.